NASDAQ$ROIV

Roivant Sciences Ltd · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Headline financials

Total Revenue

$14M

No prior period
Capital Expenditures

-$5.1M

No prior period
Free Cash Flow

-$214M

No prior period
Net Income

-$208M

No prior period
Operating Income

-$684M

No prior period
Cash & Equivalents

$2.5B

No prior period
Total Assets

$3.1B

No prior period

Revenue & EPS history

Roivant Sciences · Revenue · Quarterly

$14M

Q2 2021
Beat estimate in 6 of 10 quarters(60%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+3.3%

Avg return

Earnings day

+1.0%

Avg return

5 days after

+1.0%

Avg return

30 days after

60%

12 / 20 earnings

Positive

+22.1%

Q3 2026

Best reaction

-5.5%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+14.9%+6.2%+11.4%
Q3 2026+22.1%+26.8%+36.1%
Q2 2026+2.6%-1.6%-1.8%
Q1 2026-2.8%+3.1%+19.8%
Q4 2025+6.4%+5.9%+7.3%
Q4 2024-3.4%+0.0%-1.5%
Q3 2024+4.1%+6.6%-5.9%
Q2 2024+5.6%+1.8%+22.7%
Q1 2024-5.2%-6.1%-3.5%
Q4 2023+9.4%+7.8%+28.8%
Q3 2023+9.7%+8.2%+7.8%
Q2 2023+7.4%-3.1%+39.9%
Q1 2023-5.5%-15.3%-15.8%
Q4 2022-4.1%-5.6%-11.8%
Q3 2021+5.1%-3.2%-25.4%
Q3 2022+5.4%-3.2%-25.4%
Q2 2022-2.4%-4.8%+6.8%
Q2 2021-3.8%-4.8%+6.8%
Q1 2021+0.1%+0.7%-38.7%
Q1 2022+0.0%+0.7%-38.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro